Ocular Therapeutix, Inc. OCUL
6.66 USD +0.05 (+0.76%)
At closeNov 11, 2026, 6:51 PM EST
6.79 +0.13 +1.93%
After hours · Nov 11, 6:51 PM ET
6.48 Day range 6.82
6.29 52-week range 16.11
- YTD
- -45.14%
- 1 year
- -40.64%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $28 HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $25 to $28.
seekingalpha.com Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript
marketbeat.com What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call Ocular Therapeutix NASDAQ: OCUL plans to submit a U.S. application in the fourth quarter of 2026 for AXPAXLI, its investigational treatment for wet age-related macular degeneration, executives said…
zacks.com Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.37 per share a year ago.
benzinga.com Ocular Therapeutix Q3 2026 Earnings Call Transcript Ocular Therapeutix (NASDAQ:OCUL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Ocular Therapeutix Q3 EPS $(0.42) Misses $(0.36) Estimate, Sales $12.874M Miss $14.339M Estimate Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 10.53 percent decrease over losses…
globenewswire.com Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting,…
globenewswire.com Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina…
defenseworld.net Critical Analysis: Lyra Therapeutics (OTCMKTS:LYRA) and Ocular Therapeutix (NASDAQ:OCUL) Ocular Therapeutix (NASDAQ: OCUL - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare…
globenewswire.com Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026 BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today…
globenewswire.com Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today…
seekingalpha.com Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity Ocular Therapeutix is rated Buy (speculative) with a 12-month price target of $7.90, reflecting a lopsided risk/reward profile. AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path,…
seekingalpha.com Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript
marketbeat.com Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win Ocular Therapeutix NASDAQ: OCUL is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration,…
benzinga.com Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.
benzinga.com UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14 UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.
globenewswire.com Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted…
benzinga.com Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.
globenewswire.com Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today…- benzinga.com Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.
marketbeat.com Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel…
globenewswire.com Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina…
benzinga.com HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $25 price target.- benzinga.com Ocular Therapeutix Announces Completion Of Pre-NDA Meeting With FDA For Investigational Product Candidate AXPAXLI For Treatment Of Wet Age-Related Macular Degeneration Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory…
globenewswire.com Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence…
globenewswire.com Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today…
defenseworld.net BlackRock Inc. Invests $190.28 Million in Ocular Therapeutix, Inc. $OCUL BlackRock Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ: OCUL) in the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 19,376,555 shares of…
seekingalpha.com Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
benzinga.com Why Is Ocular Therapeutix Stock Gaining Monday? Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).
benzinga.com Why Is Ocular Therapeutix Stock Gaining Monday? Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.
benzinga.com H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved…
benzinga.com Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 10.26 percent. This is a 10.26 percent increase over losses of…- benzinga.com Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23 Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25 HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $25.
- benzinga.com Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30 Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $24 to $30.
benzinga.com Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.
benzinga.com Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028 Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety dataOcular to conduct interim SOL-R safety analysis in 4Q 2026 to reach…
benzinga.com Ocular Therapeutix Appoints Jason Robins CFO, Effective June 10 https://www.sec.gov/ix?doc=/Archives/edgar/data/1393434/000110465926073496/tm2617802d1_8k.htm
benzinga.com Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.- benzinga.com RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and maintains $30 price target.
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Ocular Therapeutix Q1 EPS $(0.40) Misses $(0.33) Estimate, Sales $10.785M Miss $12.599M Estimate Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.33) by 21.21 percent. This is a 5.26 percent decrease over losses of…
benzinga.com Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal diseases and on track for FDA submission.- benzinga.com HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $21 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $21 price target.
- benzinga.com Ocular Therapeutix Reports One-Year Results For Eye Disease Treatment Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company committed to redefining the retina experience, today announced additional positive Week 52 data from the…
- benzinga.com EyePoint Files Lawsuit Against Ocular Therapeutix Alleging Defamation And Misleading Claims Over DURAVYU Clinical Results On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeutix, Inc. (the "Defendant") in the Middlesex County Superior Court for the Commonwealth of Massachusetts…
benzinga.com GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raised to $28, MDB cut to $260, RIOT cut to $23, DAVE raised to $295, NTST raised to $22, U raised to $19,…
benzinga.com Clear Street Maintains Buy on Ocular Therapeutix, Raises Price Target to $28 Clear Street analyst Bill Maughan maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $28.
benzinga.com Gold Down 3%; Medtronic Earnings Top Views